DBV Technologies | DBVT - Pre Tax Profit


DBV Technologies reported $-33.16M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -852K 7.26M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
United Therapeutics USD 444M 6M Dec/2025